🇺🇸 FDA
Pipeline program

Vericiguat, Vericiguat, Vericiguat, Vericiguat

MK-1242-043

Phase 3 small_molecule active

Quick answer

Vericiguat, Vericiguat, Vericiguat, Vericiguat for Heart Failure due to Systemic Left Ventricular Systolic Dysfunction is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Heart Failure due to Systemic Left Ventricular Systolic Dysfunction
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials